FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Highlighting the multifaceted benefits of GHK in tissue repair and protection, emphasizing its potential as a therapeutic agent in regenerative medicine.
研究ライブラリに戻る
GHKGHK-Cu

Highlighting the multifaceted benefits of GHK in tissue repair and protection, emphasizing its potential as a therapeutic agent in regenerative medicine.

May 17, 2026
Share

元の論文

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.

Pickart Loren et al.International journal of molecular sciences2018
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

GHK: A Multi-Faceted Peptide with Regenerative Potential

Published: May 17, 2026 | Source: International journal of molecular sciences (2018) | Category: GHK, GHK-Cu

Overview

A recent review in the International Journal of Molecular Sciences highlights the remarkable regenerative and protective properties of a human peptide known as GHK. This peptide shows promise for various therapeutic applications due to its ability to stimulate tissue repair across multiple organs and exhibit potent anti-inflammatory and anticancer activities.

Study Background

GHK, or glycyl-l-histidyl-l-lysine, has been the subject of numerous studies over the years for its diverse biological effects. However, until recently, the underlying mechanisms behind these actions were not fully understood. This review synthesizes existing knowledge on GHK and incorporates new genetic data to elucidate how this peptide exerts its beneficial effects.

What the Research Found

The review outlines several key findings regarding GHK:

  • Tissue Repair: GHK stimulates tissue repair in various organs, including skin, lungs, bone, liver, and stomach lining.
  • Collagen Synthesis: It increases collagen synthesis, which is crucial for wound healing and maintaining structural integrity of tissues.
  • Anti-Inflammatory Actions: GHK exhibits strong anti-inflammatory properties, potentially beneficial in conditions like chronic obstructive pulmonary disease (COPD).
  • Anticancer Activities: The peptide shows multiple anticancer effects, suggesting potential use as an adjuvant therapy in cancer treatment.

What This Means for Peptide Users

For those interested in peptides for therapeutic purposes, GHK presents a promising candidate due to its broad range of beneficial actions. However, it is important to note that while the review highlights these positive attributes, further clinical trials are necessary to confirm efficacy and safety in humans.

Limitations and Caveats

As this is a review paper, it does not present new experimental data but rather synthesizes existing knowledge. The limitations include:

  • Limited High-Quality Studies: There may be insufficient high-quality studies on GHK.
  • Mechanistic Uncertainty: While genetic data suggest multiple pathways regulated by GHK, the exact mechanisms remain to be fully elucidated.

How This Compares to Previous Research

This review builds upon earlier research that had already identified beneficial effects of GHK but lacked a comprehensive understanding of its molecular basis. The inclusion of new gene data provides a more detailed framework for how GHK functions at the cellular level, aligning with and expanding on previous findings.

Our Analysis

PeptideVault views this review as an important contribution to the field, offering valuable insights into the multifaceted benefits of GHK. However, it is crucial to approach these findings with caution until more robust clinical evidence is available. The potential therapeutic applications are intriguing but require further investigation.

Key Takeaways

  • Regenerative Potential: GHK shows promise in stimulating tissue repair across various organs.
  • Anti-Inflammatory and Anticancer Effects: It possesses potent anti-inflammatory properties and exhibits multiple anticancer activities.
  • Further Research Needed: While the review highlights numerous benefits, more clinical trials are necessary to confirm these effects.

Original Source

Citation: Pickart Loren, Margolina Anna (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International journal of molecular sciences. DOI: 10.3390/ijms19071987

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。